Artificial Intelligence is seeing unprecedented growth in almost every field. When it comes to healthcare, the practice and real-world application of AI is truly seen and felt here. While there are so many companies researching, developing, and making extensive use of AI, Biovista is taking a new route to infuse AI technology in healthcare.
The company’s AI platform is applied for the development of repositioned drug candidates in disease areas. This includes orphan diseases, epilepsy, oncology, and neurodegenerative diseases. Working with collaborators, Biovista proactively positions assets- be it existing compounds or chemical entities.
Scientists at the company use the in-house technology to “analyze massive data resources and identify non-obvious, mechanism-of-action based associations between compounds, molecular targets and diseases.” Research is also extended to assess the risk profile and advance them to PoC and Clinical Phase IIa/b. The benefit? It’s a pathway to discover new users for drug combinations or existing drugs that help to bring out quicker and cheaper results that tag along a higher probability of success.
Visionary in Healthcare
Every company has a set of visions and goals when they establish. Biovista is constantly thinking of new ways to innovate therapies more efficiently than how it was done previously. Biovista understands that healthcare providers, payers, and patients are constantly expecting more for less. The industry too is always looking for answers to deliver this demand- and this extends especially to Biovista.
Biovista is researching and developing new treatments which haven’t been a reality so far. It’s also working to improve existing offerings to make it simpler, clearer, and more meaningful for all. At the same time, Biovista also understands that to properly exploit any newfound insight, novel collaboration models and organizational frameworks are needed; something that is flexible and exploitable in an efficient and manageable manner.
It’s also interesting to know about Biovista’s Project Prodigy. It’s a technology platform and the company’s long-term initiative to bring out next-gen Augmented Intelligence healthcare solutions. Biovista explains Project Prodigy is something that “combines capabilities in AI and Machine Learning, Natural Language Processing, graph databases, federated system architectures and collaborative work UIs to create solutions that support discovery and knowledge intensive analytics in healthcare and other commercial environments.”
Biovista Challenges Healthcare
Biovista chalks out some of the major challenges that are faced in healthcare:
The list goes on and it’s clear that all of these challenges are- well, challenging! If you consider our limited knowledge of biological systems and processes, it is quite incomplete. We still don’t have the complete knowledge of how a drug works on our bodies or how exactly a disease modulates the healthy state. But Biovista is confident that even though our knowledge is limited, it can still have a significant impact on the bottom line when we unearth, interpret, and organize the hidden associations in our knowledge.
‘Augmented Intelligence for better decision making’
At Biovista, the focus is on empowering multi-disciplinary teams, where subject-matter experts and powerful platform technologies are amalgamated to develop and deliver custom solutions. It could be a drug or even a molecular target of immediate business relevance to partners; Biovista channels all its attention to developing new innovative solutions. The business model here is a combination of in-house core strengths and strategic partnering to create synergies. This unique combination is certainly transforming everything en route to drug discovery and development.
Aris Persidis, President and Co-Founder
Dr. Persidis has served as Senior Vice President at Upstate/Serologicals, Managing Director and President of RHeoGene, and Assistant Director-Medical School Technology Transfer Program – and Assistant Professor (Adjunct) at the Entrepreneurial Center of the Wharton School of Business at the University of Pennsylvania (1993-1997). He is also a co-founder of Cellzome, in Heidelberg, Germany, and participated in the founding of Anadys, San Diego, CA. Dr. Persidis is a recipient of the Honeywell European Futurist Award (1986) and has published extensively on bio-business subjects.
Back in 1997-2000, Dr. Persidis authored the monthly “Industry Trends” column for the journal Nature Biotechnology. He has published more than 80 papers and book chapters, has lectured at Wharton, the Columbia Business School, George Washington University and the University of Auckland Business School, and is a frequent speaker at major international meetings. He also serves as an expert evaluator for the European Union and has served on the Business Development Committee of BIO. Dr. Persidis holds a First Class B.Sc. Degree in biological chemistry from Essex University, U.K. (1983-1986), and a Ph.D. in biochemistry from the University of Cambridge, U.K. (1986-1989), where he was also U.K. varsity ballroom dancing champion.
“At Biovista we believe that from better decisions stem better therapies and from these the benefits of better healthcare.”
“We believe that patients, healthcare providers and payers are now expecting more for less and that the industry is looking for new ways to deliver on this need.”
Founder Kishore Biyani explains the exit of Future Group from retail business
Carl Pei leaves OnePlus to start a new venture
India's Razorpay Turns Unicorn after Latest Funding Round
Apple, Samsung along with 14 other companies to boost local electronics manufacturing
Amazon sends legal notice to Future Group over Reliance Retail deal
© 2020 CIO Bulletin. All rights reserved.